Hydrochlorothiazide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Hydrochlorothiazide
- Hydrochlorothiazide: From Hypertension to Multiple Candidate Indications (10-Candidate Evidence Pack)
Hydrochlorothiazide: From Hypertension to Multiple Candidate Indications (10-Candidate Evidence Pack)
One-Sentence Summary
Hydrochlorothiazide (HCTZ, DrugBank DB00999) is a thiazide diuretic long used clinically to manage hypertension and oedema, though no formal approved-indication text or marketing license is present in this dataset (drug currently not marketed in the covered jurisdiction). The TxGNN model surfaced 10 candidate indications, led by Malignant Hypertensive Renal Disease (score 98.42%), but only 2 of the 10 candidates — chronic and acute pulmonary heart disease (cor pulmonale) — have any supporting clinical trial or literature evidence (2 trials, ~17 relevant publications combined); the remaining 8 candidates are supported by the model score alone (L5, no trials, no literature).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in this dataset (0 licenses on file); HCTZ is globally known as a thiazide diuretic for hypertension and oedema |
| Predicted New Indication (top-ranked) | Malignant Hypertensive Renal Disease (9 additional candidates evaluated — see table below) |
| TxGNN Prediction Score (top-ranked) | 98.42% |
| Evidence Level (top-ranked) | L5 (model prediction only) |
| Best-Evidence Candidate | Acute Pulmonary Heart Disease — L3, decision stage S2 |
| Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold (top-ranked candidate); Research Question for the two cor pulmonale candidates |
All Predicted Indications — Overview
| Rank | Disease | TxGNN Score | Evidence Level | Decision Stage | Recommendation |
|---|---|---|---|---|---|
| 1 | Malignant hypertensive renal disease | 98.42% | L5 | S0 | Hold |
| 2 | Malignant renovascular hypertension | 98.42% | L4 | S0 | Hold |
| 3 | Pulmonary hypertension owing to lung disease/hypoxia | 98.35% | L5 | S0 | Hold |
| 4 | Pulmonary hypertension, unclear multifactorial mechanism | 98.35% | L5 | S0 | Hold |
| 5 | Braddock syndrome | 97.92% | L5 | S0 | Hold |
| 6 | Chronic pulmonary heart disease | 97.80% | L3 | S1 | Research Question |
| 7 | Acute pulmonary heart disease | 93.17% | L3 | S2 | Research Question |
| 8 | Primary hereditary glaucoma | 90.87% | L5 | S0 | Hold |
| 9 | Open-angle glaucoma | 86.16% | L5 | S0 | Hold |
| 10 | Hypotrichosis simplex of the scalp | 74.54% | L5 | S0 | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for Hydrochlorothiazide is not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on established pharmacology, HCTZ is a thiazide-class diuretic that inhibits the Na⁺/Cl⁻ cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption; its clinical efficacy in hypertension and fluid overload/oedema is well established.
For the top-ranked candidates (malignant hypertensive renal disease, malignant renovascular hypertension, pulmonary hypertension subtypes, glaucoma, Braddock syndrome), the mechanistic link is weak or purely theoretical — these candidates carry high TxGNN scores but no direct experimental or clinical support. Two notable caveats from the rationale data:
- HCTZ (like other thiazides) carries a known safety signal for acute angle-closure glaucoma, which is the opposite of a therapeutic effect for glaucoma candidates (ranks 8–9) — this should be treated as a safety flag, not a repurposing opportunity.
- The 20 literature hits under “pulmonary hypertension owing to lung disease/hypoxia” are mostly generic hypoxia-biology papers (brain aging, cancer metabolism, immunology) matched only on the keyword “hypoxia,” not genuine HCTZ-disease evidence.
The two candidates with actual clinical support — chronic pulmonary heart disease and acute pulmonary heart disease (cor pulmonale) — are mechanistically plausible in a narrower, symptomatic sense: both conditions frequently present with right heart failure and systemic congestion, and thiazide diuretics (including HCTZ) are an established adjunct to loop diuretics for decongestive therapy in heart failure (e.g., the CLOROTIC trial combining HCTZ with furosemide). This is a supportive/symptomatic rationale, not evidence that HCTZ modifies the underlying pulmonary vascular or cardiac disease process.
Clinical Trial Evidence
Only the acute pulmonary heart disease candidate has registered clinical trials on file; no trials were found for any of the other 9 candidates.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT07008365 | Phase 3 | Recruiting | 168 | Uses intra-abdominal pressure and POCUS to guide decongestive/diuretic therapy in acute heart failure; relevant to diuretic-class congestion management but not HCTZ-specific (Relevance grade B). |
| NCT06273397 | Not applicable | Not yet recruiting | 1050 | Compares acetazolamide vs. metolazone (a thiazide-like diuretic, same class as HCTZ) added to standard therapy in acute heart failure decongestion (Relevance grade B). |
For the remaining 8 candidates (malignant hypertensive renal disease, malignant renovascular hypertension, both pulmonary hypertension subtypes, Braddock syndrome, chronic pulmonary heart disease, both glaucoma types, hypotrichosis): currently no related clinical trials registered.
Literature Evidence
Below are the most relevant publications across the two evidence-supported candidates (chronic/acute pulmonary heart disease) and the tangential single-paper candidates. The 20 hits returned for “pulmonary hypertension owing to lung disease/hypoxia” were excluded as false-positive keyword matches (generic hypoxia biology, unrelated to HCTZ or the target disease).
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38215973 | 2024 | RCT (post-hoc/subgroup) | Revista Clínica Española | CLOROTIC trial: adding HCTZ to furosemide improved diuretic response in acute heart failure; this analysis examines sex-based outcome differences. |
| 11219471 | 2001 | RCT | Clinical Therapeutics | 26-week randomized multicenter trial comparing telmisartan vs. atenolol, with HCTZ added as needed, in mild-to-moderate hypertension. |
| 1916562 | 1991 | Controlled trial | Fortschritte der Medizin | Verapamil + triamterene/HCTZ combination improved hemodynamics (BP, heart rate) in chronic heart failure over 4 weeks. |
| 2924690 | 1989 | Crossover study | Deutsche Medizinische Wochenschrift | Compared HCTZ+triamterene diuretic combination vs. digitalis in chronic heart failure (n=16); diuretic reduced pulmonary wedge pressure. |
| 36595088 | 2023 | Review | European Journal of Pediatrics | Reviews diuretic classes (including thiazides) for congestive heart failure and pulmonary hypertension in pediatric patients. |
| 33224781 | 2020 | Case report | Cardiovascular Diagnosis and Therapy | Mineralocorticoid receptor blockade improved pulmonary hypertension/RV function in an infant with bronchopulmonary dysplasia (diuretic-class relevance, not HCTZ-specific). |
| 28711447 | 2017 | Review | JACC: Heart Failure | Reviews the pathophysiological transition from hypertension to heart failure, relevant background for cor pulmonale congestion management. |
| 17269602 | 2007 | Case report | Clinical Nephrology | Heart and renal failure secondary to renovascular hypertension from giant cell arteritis; tangential relevance to malignant renovascular hypertension candidate. |
| 6292087 | 1982 | Case report | Hypertension (Dallas) | Severe hypertension in a neurofibromatosis patient with renal artery stenosis; the only literature hit for “malignant renovascular hypertension,” not HCTZ-specific. |
No literature was found for: malignant hypertensive renal disease, pulmonary hypertension (unclear multifactorial mechanism), Braddock syndrome, primary hereditary glaucoma, open-angle glaucoma, or hypotrichosis simplex of the scalp.
Market Information
Currently no marketing authorization records are available for Hydrochlorothiazide in this jurisdiction’s dataset — 0 licenses on file, market status: Not Marketed. No product name, dosage form, or approved-indication text could be extracted.
Safety Considerations
Please refer to the official package insert (label/SmPC) for safety information — no structured warnings, contraindications, or drug-interaction data are currently available in this dataset.
Note: retrieval of the TFDA-equivalent package insert (warnings/contraindications) is flagged as a Blocking data gap (DG001) — this must be resolved before any candidate here can undergo an initial safety assessment, independent of how promising the efficacy evidence is.
Conclusion and Next Steps
Decision: Hold (for the dataset as a whole), with chronic/acute pulmonary heart disease carried forward as Research Questions
Rationale:
- 8 of the 10 TxGNN-predicted indications (including the top-ranked “malignant hypertensive renal disease”) are supported by the model score alone, with zero clinical trials or literature — insufficient to justify any action beyond monitoring (L5, Hold).
- The two candidates with real supporting evidence — chronic pulmonary heart disease (L3) and acute pulmonary heart disease (L3) — reflect HCTZ’s known role as an adjunct diuretic for congestion management in heart failure, not a disease-modifying mechanism for the pulmonary vascular disease itself; neither of the two registered trials studies HCTZ directly (one uses a POCUS-guided general diuretic protocol, the other compares acetazolamide vs. metolazone).
- A Blocking data gap (missing TFDA/label safety data) prevents any candidate from proceeding to a formal safety pre-assessment regardless of efficacy evidence strength.
To proceed, the following is needed:
- Official package insert / SmPC (warnings, contraindications, DDI) — Blocking gap, DG001
- Detailed mechanism-of-action data via DrugBank API — High-priority gap, DG002
- Confirmation of HCTZ’s regulatory/marketing status in the target jurisdiction (currently 0 licenses on file)
- For the cor pulmonale candidates: trial-level data confirming HCTZ (not just diuretics/thiazide-like agents in general) is the active study drug, before advancing past the current Research Question stage
- Independent clinical review of the glaucoma candidates given HCTZ’s known association with acute angle-closure glaucoma as an adverse effect (safety signal, not a repurposing rationale)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.